Longer Maintenance Therapy Duration May Improve Survival in Myeloma

Longer Maintenance Therapy Duration May Improve Survival in Myeloma
Longer Maintenance Therapy Duration May Improve Survival in Myeloma

A longer duration of lenalidomide maintenance therapy after autologous hematopoietic stem cell transplantation (HSCT) may improve progression-free and overall survival in patients with multiple myeloma, according to a study published in the journal Cancer.1

Although maintenance therapy with lenalidomide has demonstrated improved clinical outcomes following autologous HSCT among patients with multiple myeloma, the ideal duration of therapy remains unclear.

For the study, investigators analyzed data from 464 patients with multiple myeloma who were receiving lenalidomide after autologous HSCT between 2007 and 2013. Of those, 46% began therapy less than 4 months after autologous HSCT.

Results showed that median progression-free survival was 38 months and median overall survival was 78 months. Investigators found that lenalidomide treatment for greater than 2 years was associated with an 87% reduction in the risk of progression (hazard ratio [HR], 0.13; 95% CI, 0.04-0.38; P <.001) and a 91% decrease in the risk of death (P <.001) compared with those on maintenance therapy for 2 years or less.

Researchers further observed a trend toward improved progression-free survival (HR, 0.02; 95% CI, 0.00-0.44; P =.012) and overall survival (HR, 0.05; 95% CI, 0.00-0.83; P =.037) for patients treated for more than 3 years vs those on maintenance for 3 years or less.

There was no difference in survival between patients who initiated maintenance lenalidomide less than 4 months after autologous HSCT and those who began treatment 4 or more months afterward.

The study also demonstrated that the incidence of secondary primary malignancies among all patients was 3%.

Reference

1. Mian I, Milton DR, Shah N, et al. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016 Sep 28. doi: 10.1002/cncr.30366. [Epub ahead of print]

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs